心血管药物开发商Braveheart Bio（BRVE）今日在纳斯达克首日上市交易，盘中股价大涨67.78%，引发市场广泛关注。
消息面上，该公司此次IPO获得投资者强劲需求，发行规模从原计划的1875万股扩大至约2130万股，发行价定为每股18美元，突破了此前15至17美元的指导区间上限，募资总额达3.825亿美元。该股开盘价报每股25美元，较发行价大幅溢价。
Braveheart Bio总部位于加州旧金山，是一家处于临床后期的生物制药公司，专注于开发肥厚型心肌病及其他严重心血管疾病的创新疗法。公司由顶级风投Andreessen Horowitz（a16z）支持，百健首席执行官Christopher Viehbauer担任董事长，核心候选药物BHB-1893瞄准百亿级肥厚型心肌病市场。此次IPO由高盛、杰富瑞、道明考恩、斯蒂费尔和坎托尔担任联合簿记管理人。在2026年生物科技IPO热潮的背景下，Braveheart Bio的成功上市进一步彰显了市场对创新药企的强劲信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.